These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34133089)

  • 41. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
    Kornstein S; Chang CT; Gommoll CP; Edwards J
    Int Clin Psychopharmacol; 2018 Jul; 33(4):217-223. PubMed ID: 29608461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J; Liu XF; Feng C; Bao Q; Fu HR
    Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
    [No Abstract]   [Full Text] [Related]  

  • 43. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
    Papakostas GI; Martinson MA; Fava M; Iovieno N
    J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder.
    Christensen MC; McIntyre RS; Adair M; Florea I; Loft H; Fagiolini A
    CNS Spectr; 2023 Dec; 28(6):693-701. PubMed ID: 37070529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition.
    Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS
    Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
    Li G; Wang X; Ma D
    Neuropsychiatr Dis Treat; 2016; 12():523-31. PubMed ID: 27013879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
    Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
    Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
    [No Abstract]   [Full Text] [Related]  

  • 58. Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.
    Kotzalidis GD; Lombardozzi G; Matrone M; Amici E; Perrini F; Cuomo I; De Filippis S
    Curr Neuropharmacol; 2021; 19(12):2296-2307. PubMed ID: 33441069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.
    Inoue T; Fujimoto S; Marumoto T; Kitagawa T; Ishida K; Nakajima T; Moriguchi Y; Fujikawa K; Watanabe K
    Neuropsychiatr Dis Treat; 2021; 17():3781-3790. PubMed ID: 34992372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.